Wegovy Tablets
- ✓
Daily pill instead of weekly injection - ✓
Average ~17% body weight loss - ✓
3 in 10 patients lost 20% or more of starting weight - ✓
Weight management may be suitable for patients with a BMI of 25 or more*
- Free Delivery
- Clinical Reviews
- Easy to Manage
- Track your Savings
- ✓
No needles or storage condition - ✓
Average 17% body weight loss in phase 3 trials - ✓
1 in 4 patients lost 20% or more of starting weight - ✓
Weight management may be suitable for patients with a BMI of 25 or more
Refer a friend: Both get £40
All doses are available to order now.
Wegovy tablets are a once-daily weight loss pill containing semaglutide, the same active ingredient used in the Wegovy injection.
Wegovy Tablets Price
At The Family Chemist, we strive to offer affordable private care, regularly checking our prices against competitors to ensure you get the best value for money.
| Wegovy Dosage | Monthly plan | Subscribe & Save | Timeline |
|---|---|---|---|
| 1.5mg (30 Tablets) | £105.00 |
£85.00/renewal
|
Weeks 1-4
Starting dose
|
| 4mg (30 Tablets) | £129.99 |
£109.99/renewal
|
Weeks 5-8
Step 2
|
| 9mg (30 Tablets) | £149.99 |
£129.99/renewal
|
Weeks 8-12
Step 3
|
| 25mg (30 Tablets) | £199.99 |
£179.99/renewal
|
Onwards
Maintenance
|
Save £20 every month
Subscribe & Save on popular treatments
Never miss your next dose. Your treatment can be prepared automatically every month, with a quick check-in before each order.
Subscribe & Save
Best Value
- Auto-renews every 4 weeks
- Quick monthly check-in
- Choose to stay on the same dose, increase, decrease, or pause
- Cancel anytime
One-time purchase
Best Value
- Single order only
- No ongoing savings
- Reorder manually each month
Subscribe & Save
Best Value
- Auto-renews every 4 weeks
- Quick monthly check-in
- Choose to stay on the same dose, increase, decrease, or pause
- Cancel anytime
One-time purchase
Best Value
- Single order only
- No ongoing savings
- Reorder manually each month
Your journey
starts here
More than medication. Our pharmacists provide expert support designed to help you succeed.
Start Free Consultation
Complete a quick, free online questionnaire.
Clinician Review
After you choose your preferred treatment, our clinicians will review your consultation.
Delivered to your door
Your medication is approved and delivered quickly in discreet packaging.
Access your coaching
Activate your access code in the Nutrable app to access personalised nutrition guidance and coaching features.
“Oral semaglutide is a significant milestone for treating obesity in the UK. Patients will now have access to a clinically proven GLP-1 therapy in tablet form, so people who are put off by injections now have another option”
Dr James Pawleck – Medical Director
About Wegovy Tablets
What are Wegovy tablets?
The Wegovy tablet is a once-daily oral alternative to the weekly injection and supports weight loss. Both contain the same active ingredient, semaglutide, but the Wegovy tablet contains an absorption enhancer called SNAC, to protect semaglutide as it passes through the stomach and into your bloodstream.
How does the Wegovy tablet work?
Wegovy mimics GLP-1, a hormone released after eating. It works by:
Reducing appetite: it makes you feel fuller sooner, so you get used to smaller portions and reduce cravings.
Slows digestion: it makes food stay in your stomach for longer, making you feel fuller and less likely to snack between meals
Helps regulate blood sugar: stable blood sugar levels prevent energy crashes and may reduce hunger throughout the day.
Can I buy Wegovy tablets online?
Yes, you can buy Wegovy tablets from The Family Chemist after an free, online assessment that is reviewed and approved by one of our clinicians.
Can I buy the Wegovy tablet over the counter?
No, Wegovy tablets are prescription-only; you will need a prescription from a prescriber after an online assessment to confirm you’re suitable for the medication.
How long do Wegovy tablets take to work?
Some people notice changes in their appetite within the first few weeks, but the starting doses are mainly there to help your body adjust. Weight loss usually becomes more noticable as you move up to higher doses.
The Wegovy tablet follows a 90 day dose escalation schedule, starting at 1.5 mg daily and increasing every 30 days until you reach the 25 mg maintenance dose. This gradual approach helps your body adjust and reduces side effects.
In clinical trials, participants taking 25 mg for 64 weeks saw an average weight loss of 16.6%.
Individual results vary and depend on consistent daily use, following administration instructions, and maintaining healthy lifestyle changes alongside treatment.
Wegovy Tablet dosing schedule
You start on the lowest dose and move up every 30 days. Building up slowly gives your body time to adjust and reduces side effects.
| Dose | How to take it | When | Notes |
|---|---|---|---|
| 1.5mg | Once daily | Days 1 – 30 | Starting dose |
| 4mg | Once daily | Days 31 – 60 | |
| 9mg | Once daily | Days 61 – 90 | |
| 25mg | Once daily | Days 91 onwards | Maximum dose |
Eligibility
Can I take the Wegovy tablet?
Wegovy tablets are suitable for adults who have:
- A BMI of 30 or above, or
- A BMI of 27 or above alongside a weight-related health condition, such as high blood pressure, high cholesterol, or type 2 diabetes
If you’re from a certain background such as South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background, you may be eligible if you have:
- A BMI of 27 or above, or
- A BMI of 25 or above alongside a weight-related health condition, such as high blood pressure, high cholesterol, or type 2 diabetes
Who should not take Wegovy tablets?
Wegovy tablets are not suitable for everyone. A qualified clinician will assess whether it is appropriate for you individually.
You should not take Wegovy tablets if you:
- are pregnant or planning to become pregnant or breastfeeding (stop taking Wegovy tablets at least 2 months before you try to get pregnant)
- have a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer)
- have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Are under 18 years of age.(Those aged 85+ will require individual clinical assessment)
- are allergic to semaglutide or any of the other ingredients in the tablet
You should discuss treatment with a prescriber if you:
- have a history of pancreatitis
- have severe kidney or liver disease
- have diabetic retinopathy (a complication of diabetes affecting the eyes)
- have severe gastrointestinal disease, including gastroparesis (delayed stomach emptying)
- are taking other GLP-1 receptor agonist medications, such as Wegovy injections, Ozempic, or Rybelsus
- are taking insulin or sulfonylureas (such as Gliclazide), as your dose may need lowering to avoid low blood sugar
- Take levothyroxine for an underactive thyroid, as Wegovy tablets can increase how much levothyroxine you absorb and your thyroid levels may need checking
- Take other medications every morning, as these must be taken at least 30 minutes after your Wegovy tablet so they do not reduce how much semaglutide you absorb
Results
What results can you expect from the Wegovy tablet?
In the OASIS 4 clinical trial, adults with obesity or who were overweight took the 25 mg Wegovy tablet for 64 weeks.
The results were:
- Participants lost about 17% of their body weight on average, if they took the medicine throughout the trial
- About 56% of participants lost 10% or more of their body weight
- About 30% of participants lost 20% or more of their body weight
These results are similar to those with weekly Wegovy injections. In separate trials users lost an average of 21% of their weight on injections, compared to 17% on the tablet.
The two have not been compared directly however. When including patients who did not complete the 64 week trial, the average weight loss was 13.6% for tablets and 14.9% for injections.
How to take and missed doses
How to take the Wegovy tablet
- Take 1 Wegovy tablet with a sip of water (no more than 120ml)
- Only take it on an empty stomach or at least 8 hours after you ate.
- After 30 minutes, you can eat, drink, or take other medication.
- Do not split, chew or dissolve Wegovy tablets.
- Do not take the tablet with other liquids
- Do not keep the tablet in any other packaging than the one it came in.
Tip: taking it first thing makes it easier to remember. Find a routine that works best for you.
What if I miss a dose?
If you miss a dose:
- Skip the missed dose
- Take your next tablet as normal the following morning
- Do not take a double dose to make up for a missed one
If you miss multiple doses, contact our clinical team for guidance.
Wegovy tablet comparisons
Wegovy tablet vs Wegovy injection
The tablet and the injection contain the same active ingredient, semaglutide, and produced broadly similar weight loss in separate trials, although they have not been compared directly; the difference is that one is a daily pill and the other is a weekly injection. Results below include all patients who started the trial, even if they did not take the medications for the entire length.
| Wegovy tablet | Wegovy Injection | |
|---|---|---|
| Dose | 25mg daily | 2.4mg weekly |
| Trial | OASIS 4 | STEP 1 |
| Average weight loss | 13.6% | 14.9% |
| Trial length | 64 weeks | 68 weeks |
Wegovy tablet vs Mounjaro
Mounjaro targets both GLP-1 and GIP receptors, which is why it can produce greater weight loss than Wegovy.
| Wegovy pill | Mounjaro | |
|---|---|---|
| Weight loss | 13.6% over 64 weeks (OASIS 4) | 20.2% over 72 weeks (SURMOUNT 5) |
| Delivery | Daily tablet | Weekly injection |
Wegovy tablet vs Mounjaro
Mounjaro targets both GLP-1 and GIP receptors, which is why it can produce greater weight loss than Wegovy.
| Wegovy pill | Foundayo | |
|---|---|---|
| Weight loss | 13.6% over 64 weeks (OASIS 4) | 11.2% over 72 weeks (ATTAIN-1) |
| Delivery | Daily tablet | Daily tablet |
Wegovy tablet side effects
The most common side effects of Wegovy tablets include nausea, vomiting, diarrhoea or constipation, but these usually improve over time.
To reduce side effects, the dose is increased gradually to give your body time to adjust.
Common side effects
- Dizziness
- Burping or flatulence
- Bloating or indigestion
- Reflux or heartburn
- Fatigue
- Hair loss
Less common but serious side effects
Stop taking Wegovy tablets and get medical advice straight away if you have any of these:
- Pancreatitis – severe stomach pain that spreads to your back and does not go away, with or without vomiting
- Sudden vision changes (NAION) – sudden, painless loss of vision, usually in one eye
- Gallstones – pain in the upper right of your tummy, fever, or yellowing of your skin or eyes
- A lump or swelling in your neck, hoarseness or difficulty swallowing
- Kidney injury – severe dehydration caused by vomiting and diarrhoea can damage the kidneys
- Severe allergic reaction – swelling of your face, lips, tongue or throat, or difficulty breathing (call 999)
- Low blood sugar – shakiness, sweating or confusion, mainly if you also take insulin or a sulfonylurea
- If you think you are experiencing a side effect, contact our clinical team. You can also report any suspected side effect to the MHRA Yellow Card Scheme
Storage & travel
Storing Wegovy tablets
- Keep the tablets at room temperature,
- Store in a dry place. You may not want to keep them in the bathroom if it gets too hot
- Keep the pills in the original bottle they came in, with the cap tightly closed
- Wegovy tablets come in a child-resistant bottle. Keep out of reach of children.
Travelling with Wegovy tablets
- Wegovy tablets can be carried in hand luggage
- Keep tablets in their original packaging when travelling
- Avoid leaving tablets in a hot car or in direct sunlight
Switching
If you are already taking GLP-1 medication, as a tablet or injection, our clinicians will review your current dose, how long you have been on it and how well you have tolerated it. They will then advise when to take your last dose, and what dose to start the Wegovy tablet on. Below are some guides on possible switches, however this remains at the discretion of our clinical team.
Switching from Mounjaro to Wegovy tablets
| Mounjaro injection | Wegovy tablet |
|---|---|
| 2.5mg | 4mg |
| 5mg | 9mg |
| 7.5mg | 9mg |
| 10mg | 25mg |
| 12.5mg | 25mg |
| 15mg | 25mg |
Switching from Wegovy injections to the Wegovy tablet
The tablet and injection are absorbed differently by the body; always make the switch under the guidance of a qualified prescriber.
| Wegovy injection | Wegovy tablet |
|---|---|
| 0.25mg | 1.5mg |
| 0.5mg | 4mg |
| 1mg | 9mg |
| 7.2mg, 2.4mg or 1.7mg | 25mg |
Switching from Wegovy tablet to injection
| Wegovy tablet | Wegovy injection |
|---|---|
| 1.5mg | 0.25mg |
| 4mg | 0.5mg |
| 9mg | 1mg |
| 25mg | 1.7mg or 2.4mg |
Switching from Wegovy tablet to Mounjaro
| Wegovy tablet | Mounjaro injection |
|---|---|
| 1.5mg | 2.5mg |
| 4mg | 2.5mg |
| 9mg | 5mg |
| 25mg | 10mg |
FAQs
Do Wegovy tablets affect the contraceptive tablet?
Wegovy does not appear to reduce the effectiveness of hormonal contraception directly. However, side effects such as vomiting or diarrhoea occurring shortly after taking the contraceptive tablet may affect its absorption. Additional contraceptive precautions are recommended if these side effects are present.
What should I avoid while taking Wegovy tablets?
Avoid foods that are high in fat, greasy, or very spicy, as well as excessive alcohol and high-sugar drinks. We recommend smaller, more frequent meals and staying hydrated, as this can help reduce side effects and support your weight loss journey.
Can I get Wegovy tablets on the NHS?
No. It’s not available on the NHS yet, and there are no confirmed prescribing guidelines.
NICE has not published guidance on Wegovy tablets, and there is currently no confirmed route to getting them on the NHS. Wegovy injections are available through the NHS, but specialist weight management services have waiting lists. Alternatively, you can access the Wegovy tablet by private treatment after completing a short, online consultation.
Wegovy Tablets compared to other weight loss treatments
Clinical Comparison Table
| Wegovy Tablet | Mounjaro | Mysimba | Orlistat | |
| Active Ingredient(s) | Semaglutide | Tirzepatide | Naltrexone & Bupropion | Orlistat |
| Mechanism | GLP-1 receptor agonist. Mimics fullness hormone to reduce appetite | Dual GLP-1 and GIP receptor agonist. Targets two hunger hormones simultaneously | Acts on brain regions controlling appetite and cravings | Blocks absorption of approximately one third of dietary fat |
| Administration | Once daily tablet | Once weekly injection | Twice daily tablet | Up to three times daily with meals |
| Average Weight Loss | ~17%-20% over 71 weeks | 15% to 22% over 72 weeks | ~8.1% over 56 weeks | ~3% to 5% over 12 months |
| Loss of 20% or more | 29.7% of patients | 63% of patients (15mg dose) | Not reported | Not reported |
| Key Trial | OASIS 4 (NEJM 2025) | SURMOUNT-1 (NEJM 2022) | COR programme trials | Multiple RCTs |
| NHS Availability | MHRA approved | Yes (NICE approved Dec 2024) | No (private only) | Yes |
| Availability in UK | Now | Now | Now | Now |
| Monthly cost | £89.99 to £156.99 | ~£150 – £300 | ~£60 to £80 | ~£30 to £50 |
| Needles needed | No | Yes | No | No |
| Suitable for | BMI 30+ or BMI 27+ with comorbidity | BMI 30+ or BMI 27+ with comorbidity | BMI 30+ or BMI 27+ with comorbidity | BMI 28+ |
Cross-trial comparisons should be interpreted with caution due to differences in study populations, trial design, and duration. Sources: OASIS 4 (Wharton et al, NEJM 2025), SURMOUNT-1 (Jastreboff et al, NEJM 2022), COR programme trials, NICE TA875/TA664.
Sources
Semaglutide(2024)National Library of Medicine [accessed 30th October 2026]
Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes (1998)National Library of Medicine [accessed 30th October 2026]
Development and validation of a questionnaire to evaluate patient satisfaction with diabetes disease management (2000) Diabetes Care [accessed 30th October 2026]
Once-Weekly Semaglutide in Adults with Overweight or Obesity(2021)The New England Journal of Medicine [accessed 30th October 2026]
Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist (2018) Science Translational Medicine [accessed 30th October 2026]
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (2025) The New England Journal of Medicine [accessed 30th October 2026]
Wegovy® (semaglutide) Tablet: Your Complete Guide to Wegovy Tablet (2026) Novo Nordisk [accessed 30th October 2026
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (2025) The New England Journal of Medicine [accessed 30th October 2026]
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (2025) The New England Journal of Medicine [accessed 30th October 2026]
Wegovy 25 mg tablets – Summary of Product Characteristics: Undesirable Effects (2026) emc [accessed 30th October 2026]
Wegovy 25 mg tablets – Summary of Product Characteristics: Contraindications (2026) emc [accessed 30th October 2026]
Wegovy 25 mg tablets – Summary of Product Characteristics: Posology and Method of Administration (2026) emc [accessed 30th October 2026]
First GLP-1 tablet for weight loss approved in the UK (2026) Medicines and Healthcare products Regulatory Agency [accessed 30th October 2026]
Medically
reviewed by
Last reviewed: 12th November 2026
Meet our
medical professionals
Aaliyah Nelson
Nutritional Coaching
BSc (Hons) Nutrition: 47988
Standards first
always











